Abstract:AIM: The cysteine protease cathepsin K (CatK), abundantly expressed in osteoclasts, is responsible for the degradation of bone matrix proteins, including collagen type 1. Thus, CatK is an attractive target for new anti-resorptive osteoporosis therapies, but the wider effects of CatK inhibitors on bone cells also need to be evaluated to assess their effects on bone. Therefore, we selected, among a series of synthetized isothiosemicarbazides, two molecules which are highly selective CatK inhibitors (CKIs) to test their effects on osteoblasts and osteoclasts.RESEARCH DESIGN AND METHODS: Cell viability upon treatment of CKIs were was assayed on human osteoblast-like Saos-2, mouse monocyte cell line RAW 264.7 and mature mouse osteoclasts differentiated from bone marrow. Osteoblast-induced mineralization in Saos-2 cells and in mouse primary osteoblasts from calvaria, with or without CKIs,; were was monitored by Alizarin Red staining and alkaline phosphatase activity, while osteoclast-induced bone resorption was performed on bovine slices.RESULTS: Treatments with two CKIs, CKI-8 and CKI-13 in human osteoblast-like Saos-2, murine RAW 264.7 macrophages stimulated with RANKL and mouse osteoclasts differentiated from bone marrow stimulated with RANKL and MCSF were found not to be toxic at doses of up to 100 nM. As probed by Alizarin Red staining, CKI-8 did not inhibit osteoblast-induced mineralization in mouse primary osteoblasts as well as in osteoblast-like Saos-2 cells. However, CKI-13 led to a reduction in mineralization of around 40% at 10-100 nM concentrations in osteoblast-like Saos-2 cells while it did not in primary cells. After a 48-hour incubation, both CKI-8 and CKI-13 decreased bone resorption on bovine bone slices. CKI-13 was more efficient than the commercial inhibitor E-64 in inhibiting bone resorption induced by osteoclasts on bovine bone slices. Both CKI-8 and CKI-13 created smaller bone resorption pits on bovine bone slices, suggesting that the mobility of osteoclasts was slowed down by the addition of CKI-8 and CKI-13.CONCLUSION: CKI-8 and CKI-13 screened here show promise as antiresorptive osteoporosis therapeutics but some off target effects on osteoblasts were found with CKI-13.

Natural Inhibitors Targeting Osteoclast-Mediated Bone Resorption

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors

Inhibition of cysteine protease disturbs the topological relationship between bone resorption and formation in vitro

Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K

Natural Products for Treatment of Bone Erosive Diseases: the Effects and Mechanisms on Inhibiting Osteoclastogenesis and Bone Resorption

New Natural Inhibitors of Human Cathepsin B

NVP-BHG712 against postmenopausal osteoporosis in mice by targeting Cathepsin K

Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity

Targeting Integrin-β1 Impedes Cytokine-Induced Osteoclast Differentiation: A Potential Pharmacological Intervention in Pathological Osteolysis

Identification of novel bone-resorption markers by osteoclasts in vitro and in vivo

Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases

Cathepsin K: The Action in and Beyond Bone

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture

Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae As Potential Candidates for the Treatment of Osteoporosis.

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation

Inhibitory Effects of 2N1HIA (2-(3-(2-fluoro-4-methoxyphenyl)-6-oxo-1(6h)-pyridazinyl)-n-1h-indol-5-ylacetamide) on Osteoclast Differentiation Via Suppressing Cathepsin K Expression.

Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation.

Synthesis of Heterocyclic Ring-Fused Tricyclic Diterpene Analogs As Novel Inhibitors of Rankl-Induced Osteoclastogenesis and Bone Resorption

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts